Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Mortality in intracoronary versus intravenous abciximab.

Iddriss A.

Lancet. 2012 Jul 7;380(9836):25; author reply 26. doi: 10.1016/S0140-6736(12)61119-2. No abstract available.

PMID:
22770453
2.

Mortality in intracoronary versus intravenous abciximab.

Gupta A, Sharma YP.

Lancet. 2012 Jul 7;380(9836):25-6; author reply 26. doi: 10.1016/S0140-6736(12)61120-9. No abstract available.

PMID:
22770452
3.

Abciximab during percutaneous coronary intervention for ST-segment elevation myocardial infarction: intracoronary, intravenous, or not at all?

Bittl JA.

J Am Coll Cardiol. 2013 Apr 2;61(13):1455-7. doi: 10.1016/j.jacc.2013.01.042. Epub 2013 Feb 27. No abstract available.

4.

AIDA STEMI: no benefit for intracoronary abciximab.

Bertrand OF, Jolly S.

Lancet. 2012 Mar 10;379(9819):875-7. doi: 10.1016/S0140-6736(12)60079-8. Epub 2012 Feb 21. No abstract available.

PMID:
22357108
5.

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G.

Lancet. 2012 Mar 10;379(9819):923-31. doi: 10.1016/S0140-6736(11)61872-2. Epub 2012 Feb 21.

PMID:
22357109
6.

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.

Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators..

Am Heart J. 2010 Apr;159(4):547-54. doi: 10.1016/j.ahj.2009.12.038.

PMID:
20362711
7.

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.

Eitel I, Wöhrle J, Suenkel H, Meissner J, Kerber S, Lauer B, Pauschinger M, Birkemeyer R, Axthelm C, Zimmermann R, Neuhaus P, Brosteanu O, de Waha S, Desch S, Gutberlet M, Schuler G, Thiele H.

J Am Coll Cardiol. 2013 Apr 2;61(13):1447-54. doi: 10.1016/j.jacc.2013.01.048. Epub 2013 Feb 27.

8.

Intracoronary glycoprotein IIb/IIIa inhibitors downstream of the coronary occlusion: the "highway" to periphery.

Iancu AC, Ober C.

J Am Coll Cardiol. 2013 Jul 30;62(5):481. doi: 10.1016/j.jacc.2013.04.052. Epub 2013 May 20. No abstract available.

9.

Reply: To PMID 23466078.

Eitel I, Desch S, Thiele H.

J Am Coll Cardiol. 2013 Jul 30;62(5):481-2. doi: 10.1016/j.jacc.2013.05.009. Epub 2013 May 20. No abstract available.

10.
11.
12.

Coronary artery stenting in MI and Abciximab: a necessary combination?

Block PC.

Cathet Cardiovasc Diagn. 1997 Oct;42(2):180. No abstract available.

PMID:
9377647
13.

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.

De Luca G, Verdoia M, Suryapranata H.

Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Review.

PMID:
22483166
14.
15.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

16.

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.

van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bär FW, van den Brand MJ, Simoons ML, Verheugt FW.

J Am Coll Cardiol. 1999 May;33(6):1528-32.

17.

[Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].

Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ.

Rev Esp Cardiol. 2006 Jun;59(6):567-74. Spanish.

18.

Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.

Desch S, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Pauschinger M, Kerber S, Kleinertz K, de Waha S, Eitel I, Schuler G, Thiele H.

J Am Coll Cardiol. 2013 Sep 24;62(13):1214-5. doi: 10.1016/j.jacc.2013.06.014. Epub 2013 Jul 10. No abstract available.

19.

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.

Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.

Platelets. 2012;23(4):274-81. doi: 10.3109/09537104.2011.619602. Epub 2011 Oct 11.

PMID:
21988317
20.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

Supplemental Content

Support Center